An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Hutchmed
Hutchmed
Werewolf Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Celgene
Baylor College of Medicine
Ipsen
AstraZeneca
Celgene
OrphAI Therapeutics
National Cancer Institute (NCI)
Genentech, Inc.
Stanford University
Stanford University
Nordic Nanovector
Nordic Nanovector
Medical College of Wisconsin
Eisai Inc.
National Institutes of Health Clinical Center (CC)
Amgen
Brown University
Calithera Biosciences, Inc
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
Menarini Group
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Gilead Sciences
Columbia University
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
Duke University
GlaxoSmithKline
Celgene
Pfizer
Dartmouth-Hitchcock Medical Center
National Institutes of Health Clinical Center (CC)
MedImmune LLC
GlaxoSmithKline
Aptevo Therapeutics
Massachusetts General Hospital
Amgen
Otsuka Pharmaceutical Co., Ltd.
Amgen Research (Munich) GmbH
Mast Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.